#USA #Boston #Investor Conferences #Immunic #Neurologic Therapies

Immunic, Inc. to Engage Investors at Upcoming Conferences in July

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company recognized for developing cutting-edge oral therapies intended for neurologic ailments, has announced its participation in a series of investor conferences throughout July. This engagement reflects the company's commitment to transparency and collaboration with the investment community as it pushes forward with advancements in therapeutic strategies for neurological conditions.

Conferences Schedule

The following are key events where Immunic's leadership will be engaging:

• - July 14-15: Leerink Partners Therapeutics Forum

The team at Immunic, including CEO Erik Lundgren and COO Jason Tardio, will participate in one-on-one meetings during this therapeutic forum held in Boston. Investors interested in scheduling discussions can reach out to their Leerink representatives or contact Jessica Breu, VP of Investor Relations and Communications at Immunic, directly at [email protected].

• - July 16: B. Riley Securities Mind, Muscle Vision Summit

On July 16, at 1:30 PM ET, Lundgren, Tardio, and Chief Medical Officer Michael A. Panzara, M.D., M.P.H., will join a panel for a fireside chat. They will also hold one-on-one discussions with prospective investors for an in-depth conversation about Immunic's current projects and future direction. Interested parties should coordinate with their B. Riley representatives or reach out to Jessica Breu for further arrangements.

• - July 23: LifeSci Capital SF Biotech Forum

Immunic will also be represented at the LifeSci Capital SF Biotech Forum in San Francisco, where the team will continue discussions around the company's ongoing projects and future endeavors in the neurology space.

About Immunic, Inc.

Immunic, Inc. is advancing the forefront of biotechnology by developing novel oral therapies targeted at neurologic diseases. Their lead therapy, vidofludimus calcium (IMU-838), is currently undergoing phase 3 clinical trials aimed at treating relapsing multiple sclerosis, with results anticipated by the end of 2026. Prior phases have shown promising therapeutic benefits for not just relapsing-remitting multiple sclerosis but also for progressive forms of the disease and other neurological conditions.

Vidofludimus calcium uniquely combines neuroprotective capabilities as a first-in-class nuclear receptor-related 1 (Nurr1) activator with anti-inflammatory and antiviral properties by inhibiting dihydroorotate dehydrogenase (DHODH), presenting a multi-faceted approach to treatment.

Alongside IMU-838, Immunic is developing additional therapies like IMU-856 and IMU-381, which focus on a wider spectrum of neurological and autoimmune diseases, reinforcing the company’s mission to create an extensive therapeutic platform.

Looking Ahead

As Immunic capitalizes on these investor conferences in July, it also remains aware of the challenges ahead. The biotechnology landscape is fraught with uncertainties, including fluctuating economic conditions and regulatory hurdles. The company advises caution regarding forward-looking statements related to its strategic objectives and timelines.

For additional details about all upcoming events and Immunic's future initiatives, visit www.imux.com.

Keeping the lines of communication open with stakeholders is essential for Immunic as it navigates these critical developmental phases. Investors and healthcare professionals alike should keep a close eye on the outcomes of these conferences as the clinical landscape continues to evolve.